Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

Inclusion Criteria:

* Adequate renal function defined as: serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR \> 40 ml/min/m2 or \> 40 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range.
* Adequate liver function defined as: total bilirubin \< 2.5 x normal; or SGOT (AST) or SGPT (ALT) \< 5.0 x normal.
* Adequate cardiac function defined as: shortening fraction of \> 25% by echocardiogram, or ejection fraction of \> 40% by radionuclide angiogram or echocardiogram.
* Adequate pulmonary function defined as: DLCO \> 35% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% in room air.
* Diseases:

  * CML (CP, AP or BC)
  * AML/MDS/JCML
  * ALL
  * Lymphoma (Hodgkin's and non-Hodgkin's)
  * Non-malignant disorders
* Bone Marrow Failure Syndromes: Patients with the following diagnoses are eligible:

  * Severe Aplastic Anemia:
  * Fanconi Anemia
  * Severe Congenital Neutropenia (Kostmann's Syndrome)
  * Amegakaryocytic Thrombocytopenia
  * Diamond-Blackfan Anemia
  * Infantile Osteopetrosis
  * Schwachman-Diamond Syndrome
  * Dyskeratosis Congenita
  * Other bone marrow failure syndromes at discretion of Principal Investigator
* Immunodeficiencies:

  * SCIDS, all subtypes
  * Combined Immunodeficiency Syndrome
  * Wiskott-Aldrich syndrome
  * Chronic Granulomatous Disease
  * Chediak-Higashi Syndrome
  * Leukocyte Adhesion Deficiency
  * Other immunodeficiencies at discretion of Principal Investigator
* Inborn Errors of Metabolism (IEOM):

  * Transplant is recommended for the following disorders: Hurler syndrome (L-iduronidase deficiency, MPS-I), Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency, MP VI), Sly syndrome (glucuronidase deficiency, MPS-VII), Globoid cell Leukodystrophy (galactocerebrosidasedeficiency), Metachromatic leukodystrophy (arylsulfatase A deficiency), Childhood-onset X-linked adrenoleukodystrophy (X-ALD), Fucosidosis (fucosidase deficiency), Mannosidosis, Aspartylglucosaminuria, Niemann-Pick Disease Type B (acid sphingomyelinase deficiency), Gaucher disease (glucocerebrosidase deficiency) Type I (non neuropathic), Other diagnoses may be considered at the discretion of the Principal Investigator
  * For X-ALD patients greater than 5 years of age, IQ \> 80 is required. For other patients greater than 5 years of age, IQ \> 70 is required.
  * For patients less than 5 years of age, the developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g. mechanical ventilation) would not be predicted to be required in the year following transplantation.
* Histiocytosis:

  * Hemophagocytic Lymphohistiocytosis (HLH)
  * Familial Erythrophagocytic Lymphohistiocytosis
  * Langerhans Cell Histiocytosis
  * Malignant Histiocytosis
* Other Malignant and non-malignant diseases: Other malignant and non-malignant diseases not listed above may be eligible if deemed appropriate by the Principal Investigator.

Exclusion Criteria:

* Women who are pregnant and/or breast feeding are ineligible